Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

References

• Salaffi F, De Angelis R, Grassi W. MArche Pain Prevalence INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study, I: the MAPPING study. Clin Exp Rheumatol 2005;23:819–28
   PubMed Web of Science ®Google Scholar
• Leardini G, Salaffi F, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505–15
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008;371:987–97
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Burgos-Vargas R, Ambs P, et al. LITHE: tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (Pts) at 2 yrs with increasing clinical efficacy over time [abstract]. Arthritis Rheum 2009;60(10 Suppl):637
   Google Scholar
• National Institute for Health and Clinical Excellence. NICE technology appraisal guidance (130): adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Issued October 2007. http://www.nice.org.uk/nicemedia/pdf/TA130guidance.pdf. Accessed March 30, 2011
   Google Scholar
• Benucci M, Li Gobbi F, Sabadini L, et al. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFα treatment in Italian patients. Int J Immunopathol Pharmacol 2009;22:1147–52
   Google Scholar
• De Portu S, Mantovani LG, Olivieri I. Analisi di costo-utilità di abatacept nell’artrite reumatoide in Italia. Farmeconomia e Percorsi Terapeutici 2008;9:19–26
   Google Scholar
• Leardini G, Ganguly R, Singh A. Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in Italy [abstract 1152]. 67th Annual Scientific Meeting of the American College of Rheumatology (ACR), 23-28 October 2003, Orlando, FL
   Google Scholar
• Gabriel S, Drummond M, Maetzel A, et al. Patient Perspective Group. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886–90
   PubMed Web of Science ®Google Scholar
• Maetzel A, Tugwell P, Boers M, et al. OMERACT 6 Economics Research Group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891–6
   PubMedGoogle Scholar
• Kielhorn A, Porter D, Diamantopoulos A, et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin 2008;24:2639–50
   PubMed Web of Science ®Google Scholar
• Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939–46
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-(alpha) antagonists. J Rheumatol 2008;35:1745–53
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-(alpha) antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (UK) 2007;46:1345–54
   PubMed Web of Science ®Google Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221–32
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness [abstract]. Health Technol Assess 2006;10:248
   Google Scholar
• Jobanputra P, Barton P, Bryan S, et al. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1–110
   PubMedGoogle Scholar
• Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:1–91
   Web of Science ®Google Scholar
• Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425–41
   PubMed Web of Science ®Google Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006;15:1295–310
   PubMed Web of Science ®Google Scholar
• Davies R, Roderick P, Raftery J. The evaluation of disease prevention and treatment using simulation models. Eur J Operational Res 2003;150:53–66
   Google Scholar
• van Vollenhoven R, Ducournau P, Wintfeld N, et al. Health Assessment Questionnaire-Disability Index scores in patients with rheumatoid arthritis treated with tocilizumab plus conventional anti-rheumatic drugs. Presented at: ISPOR 12th Annual European Congress, 24-27 October 2009, Paris, France
   Google Scholar
• Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347–56
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Change over time in the safety, efficacy, and remission profiles of patients with rheumatoid arthritis receiving adalimumab for up to 7 years. Presented at: American College of Rheumatology 2007 Annual Scientific Meeting, 10-11 November 2007, Boston, MA
   Google Scholar
• Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793–8
   PubMed Web of Science ®Google Scholar
• Bansback N, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995–1002
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62–72
   PubMed Web of Science ®Google Scholar
• Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (HUMIRA) [abstract UT3]. Presented at: 7th International Society of Pharmacoeconomics and Outcomes Research, 19-22 May 2002, Arlington, VA
   Google Scholar
• Favalli EG, Marchesoni A, Colombo GL, et al. Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008;26:45–51
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Ordovàs Baines JP, Pla Poblador R, et al. Grupo de Investigadores del Estudio PRAXIS. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)] [Spanish]. Farm Hosp 2007;31:71–92
   Google Scholar
• Benucci M, Iannazzo S, Zaniolo O, et al. Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. Clin Exp Rheumatol 2010;28:722–7
   Google Scholar
• ISTAT Italian Institute of Statistics 2009. Coefficienti per tradurre valori monetari dei periodi sottoindicati in valori del 2010 (a). http://www.istat.it/prezzi/precon/rivalutazioni/val_moneta_2010.zip. Accessed February 7, 2011
   Google Scholar
• Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and effect of biologic therapy: a longitudinal observation study. Arthritis Res Ther 2010;12:R35
   PubMed Web of Science ®Google Scholar